Xeloda news from FiercePharma
News
ALSO NOTED: FDA: New Zyprexa sedates some;Vanderbilt outlaws rep freebies;
> Prepping for advisory panel review, FDA staff says long-lasting Zyprexa causes drowsiness. Report > Vanderbilt Medical Read more...
BMS cancer med could earn $500M
Analysts are rubbing their hands over the FDA's approval of Ixempra, a Bristol-Myers Squibb breast cancer treatment, predicting $500 million in annual sales by 2010. The drug got the agency's nod as Read more...
Get more Xeloda coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets